ID: ALA173683

Max Phase: Preclinical

Molecular Formula: C19H18N4O3S

Molecular Weight: 382.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  C#CCN(Cc1ccc2nc(C)nc(O)c2c1)c1ccc(S(N)(=O)=O)cc1

Standard InChI:  InChI=1S/C19H18N4O3S/c1-3-10-23(15-5-7-16(8-6-15)27(20,25)26)12-14-4-9-18-17(11-14)19(24)22-13(2)21-18/h1,4-9,11H,10,12H2,2H3,(H2,20,25,26)(H,21,22,24)

Standard InChI Key:  TVHGUFSMDQRRLE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 382.45

Molecular Weight (Monoisotopic): 382.1100

AlogP: 1.93

#Rotatable Bonds: 5

Polar Surface Area: 109.41

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.91

CX Basic pKa: 1.82

CX LogP: 3.13

CX LogD: 3.13

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.65

Np Likeness Score: -1.73

References

1. Jones TR, Varney MD, Webber SE, Lewis KK, Marzoni GP, Palmer CL, Kathardekar V, Welsh KM, Webber S, Matthews DA, Appelt K, Smith WW, Janson CA, Villafranca JE, Bacquet RJ, Howland EF, Booth CL, Herrmann SM, Ward RW, White J, Moomaw EW, Bartlett CA, Morse CA..  (1996)  Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.,  39  (4): [PMID:8632414] [10.1021/jm9502652]

Source

Source(1):

• Scientific Literature